Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted AJ, Frølund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H. Lund J, et al. Among authors: nahi h. Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19. Cancer Med. 2018. PMID: 29673108 Free PMC article. Clinical Trial.
The prognostic significance of 8p21 deletion in multiple myeloma.
Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. Sutlu T, et al. Among authors: nahi h. Br J Haematol. 2009 Jan;144(2):266-8. doi: 10.1111/j.1365-2141.2008.07454.x. Epub 2008 Nov 11. Br J Haematol. 2009. PMID: 19016723 Free article. No abstract available.
Constitutional inv(3) in myelodysplastic syndromes.
Gahrton C, Nahi H, Jansson M, Wallblom A, Alici E, Sutlu T, Samuelsson J, Gahrton G. Gahrton C, et al. Among authors: nahi h. Leuk Res. 2010 Dec;34(12):1627-9. doi: 10.1016/j.leukres.2010.05.014. Epub 2010 Jun 9. Leuk Res. 2010. PMID: 20542563
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Kumar SK, et al. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Leukemia. 2012. PMID: 21799510 Free PMC article.
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Hjorth M, et al. Among authors: nahi h. Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30. Eur J Haematol. 2012. PMID: 22404182 Free PMC article. Clinical Trial.
143 results